FDA Accepts Elinzanetant NDA for Menopause Symptoms and Other Health Updates
FDA Accepts Elinzanetant NDA for Vasomotor Symptoms in Menopause
The FDA has accepted the New Drug Application for elinzanetant (Bayer) for the potential treatment of moderate-to-severe vasomotor symptoms (VMS) in menopause. Clinical trials, OASIS 1 and 2, reported a reduction in VMS frequency and severity among participants receiving elinzanetant. Significant reductions were observed at week 4 and week 12, with mean frequency reductions of -3.29 and -3.22, respectively, and severity reductions of -0.33 and -0.40, respectively.
Association Between Breast Cancer and Reproductive Health
A study published in JAMA Network Open found that women in the Caribbean with breast cancer had a reduced age at menarche, fewer pregnancies, and fewer full-term pregnancies. The study also noted an increase in breast cancer cases associated with positive germline variants over time.
Lower Estradiol Linked to Abdominal Aortic Calcification Risk
Postmenopausal women with reduced Estradiol (E2) levels are more likely to experience abdominal aortic calcification (AAC), according to a study published in Frontiers in Endocrinology. The study grouped participants based on E2 tertiles and found significantly increased EACC prevalence among women with reduced E2 levels.
Reduced Opioid Dispensing After Surgery Among Youths
A decrease in opioid dispensing following surgical procedures has been reported among youths, according to a study published in JAMA Network Open. The study observed a decrease in the proportion of filled prescriptions and quality dispensed in 2017, with patients aged 18 to 20 years more likely to have preoperative prescriptions.
Transforming Public Health Through Vaccinations
Vaccinations have significantly transformed public health, reducing the incidence of many diseases and saving millions of lives. However, vaccine hesitancy has risen, fueled by misinformation and the politicization of vaccines. Combating misinformation is crucial for improving vaccine uptake, especially with the upcoming influenza and RSV seasons and continued COVID-19 surges.